A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer.

Trial Profile

A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 May 2014

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms TYTAN
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jan 2013 Primary endpoint 'Overall-survival-duration' has not been met.
    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top